Journal of Neuroimmune Pharmacology

, Volume 4, Issue 3, pp 298–308

Immune-Directed Gene Therapeutic Development for Alzheimer’s, Prion, and Parkinson’s Diseases

Invited Review

DOI: 10.1007/s11481-008-9133-3

Cite this article as:
Maguire-Zeiss, K.A. & Federoff, H.J. J Neuroimmune Pharmacol (2009) 4: 298. doi:10.1007/s11481-008-9133-3


The development of novel immune-based therapeutics for neurodegenerative diseases is an area of intense focus. Neurodegenerative diseases represent a particular challenge since in many cases the onset of symptoms occurs after considerable degeneration has ensued. Based on human genetic and histopathological evidence from patients with neurodegenerative diseases, animal models that recapitulate specific pathologic features have been developed. Utilizing these animal models in combination with viral vector-based gene therapeutics, specific epochs of disease can be targeted. One common feature of several neurodegenerative diseases is misfolded proteins. The mechanism by which these altered protein conformers lead to neurodegeneration is not completely understood but much effort has been put forward to either degrade aberrant protein or prevent the formation of misfolded conformers. In this review, we will summarize work that employs viral vector gene therapeutics to modulate the brain’s response to misfolded proteins with a specific focus on neurodegeneration.


Alzheimer’s disease prion disease Parkinson’s disease single-chain antibody active vaccination passive vaccination 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Kathleen A. Maguire-Zeiss
    • 1
  • Howard J. Federoff
    • 2
  1. 1.Department of NeuroscienceGeorgetown University Medical CenterWashingtonUSA
  2. 2.Office of the Executive Vice President and Executive DeanGeorgetown University Medical CenterWashingtonUSA

Personalised recommendations